These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 3017678)

  • 1. Post-kala-azar dermal leishmaniasis occurring long after cure of visceral leishmaniasis in Kenya.
    Rashid JR; Chunge CN; Oster CN; Wasunna KM; Muigai R; Gachihi GS
    East Afr Med J; 1986 May; 63(5):365-71. PubMed ID: 3017678
    [No Abstract]   [Full Text] [Related]  

  • 2. Post kala-azar dermal leishmaniasis: the Kenyan experience.
    Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
    East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-kala-azar dermal leishmaniasis simulating leprosy. (A case report).
    Lal S; Garg BR
    Lepr India; 1976 Jan; 48(1):81-3. PubMed ID: 191696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of kala azar and its treatment in Kenya.
    Chunge CN; Gachihi G; Chulay JD; Spencer HC
    East Afr Med J; 1984 Feb; 61(2):120-7. PubMed ID: 6088210
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verrucous papillomatous lesion of post-kala-azar dermal leishmaniasis: fine needle aspiration diagnosis of an unusual presentation.
    Bhadani PP; Sen R; Singh RK
    Acta Cytol; 2007; 51(2):252-4. PubMed ID: 17425218
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypersensitivity reaction over lesions of post-kala-azar dermal leishmaniasis mimicking type 1 reaction in leprosy.
    Dhar S; Malakar S
    Int J Lepr Other Mycobact Dis; 1999 Mar; 67(1):66-7. PubMed ID: 10407631
    [No Abstract]   [Full Text] [Related]  

  • 9. Visceral leishmaniasis (kala-azar) as a cause of fever of unknown origin.
    Geraci JE; Wilson WR; Thompson JH
    Mayo Clin Proc; 1980 Jul; 55(7):455-8. PubMed ID: 6247584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis.
    Thakur CP; Kumar K
    Indian J Med Res; 1990 Mar; 91():144-8. PubMed ID: 2160914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication.
    Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM
    Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Visceral leishmaniasis (kala-azar). A rare differential diagnosis of splenomegaly and pancytopenia].
    Baldus M; Schleiffer T; Brass H
    Dtsch Med Wochenschr; 1989 Dec; 114(48):1876-81. PubMed ID: 2555125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.
    Thakur CP; Kumar K; Sinha PK; Mishra BN; Pandey AK
    Br Med J (Clin Res Ed); 1987 Oct; 295(6603):886-7. PubMed ID: 2823955
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E; O'Flaherty D; Heuvelmans H; Seaman J; Veeken H; de Wit S; Davidson RN
    Bull World Health Organ; 2001; 79(5):388-93. PubMed ID: 11417033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.
    Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F
    Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642
    [No Abstract]   [Full Text] [Related]  

  • 16. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged sodium stibogluconate therapy in Indian kala-azar.
    Jha TK; Sharma VK
    J Assoc Physicians India; 1986 Jul; 34(7):469-71. PubMed ID: 3019993
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients.
    Kager PA; Rees PH; Manguyu FM; Bhatt KM; Wellde BT; Hockmeyer WT; Lyerly WH
    Trop Geogr Med; 1984 Mar; 36(1):21-35. PubMed ID: 6328709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroepidemiological study on kala-azar in Baringo District, Kenya.
    Jahn A; Lelmett JM; Diesfeld HJ
    J Trop Med Hyg; 1986 Apr; 89(2):91-104. PubMed ID: 3021967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral kala-azar associated with post-kala-azar dermal leishmaniasis.
    Singh NK; Agrawal SK; Jha TK
    J Assoc Physicians India; 1989 Feb; 37(2):191. PubMed ID: 2808294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.